# PCSK9 Inhibitor Treatment for Patients With SPG5

> **NCT04101643** · PHASE1,PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Fujian Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Hereditary Spastic Paraplegia Type 5

## Interventions

- **DRUG:** evolocumab

## Key facts

- **NCT ID:** NCT04101643
- **Lead sponsor:** First Affiliated Hospital of Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-29
- **Primary completion:** 2023-01-03
- **Final completion:** 2023-01-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04101643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04101643, "PCSK9 Inhibitor Treatment for Patients With SPG5". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04101643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*